BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone425-402-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$19.74 million
Profitability
Miscellaneous
Employees54
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions
What is BioLife Solutions' stock symbol?
BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."
How were BioLife Solutions' earnings last quarter?
BioLife Solutions Inc (NASDAQ:BLFS) posted its earnings results on Thursday, August, 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.02. The medical equipment provider had revenue of $6.70 million for the quarter, compared to analyst estimates of $6.59 million. BioLife Solutions had a return on equity of 8.65% and a net margin of 14.60%. View BioLife Solutions' Earnings History.
When is BioLife Solutions' next earnings date?
What guidance has BioLife Solutions issued on next quarter's earnings?
BioLife Solutions updated its FY 2019 earnings guidance on Thursday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $27.5-30.5 million, compared to the consensus revenue estimate of $28.22 million.
What price target have analysts set for BLFS?
5 Wall Street analysts have issued 1 year price targets for BioLife Solutions' stock. Their forecasts range from $5.00 to $24.00. On average, they anticipate BioLife Solutions' stock price to reach $18.40 in the next twelve months. This suggests that the stock has a possible downside of 9.3%. View Analyst Price Targets for BioLife Solutions.
What is the consensus analysts' recommendation for BioLife Solutions?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioLife Solutions.
What are Wall Street analysts saying about BioLife Solutions stock?
Here are some recent quotes from research analysts about BioLife Solutions stock:
- 1. According to Zacks Investment Research, "BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. " (7/10/2019)
- 2. Maxim Group analysts commented, "On 5/9, BioLife reported 1Q19 with $5.8M in revenue, up 51% y/y and 6% sequentially, with a gross margin of 71.5%. BioLife also reported a $0.4M net profit for the quarter and ended the period with $31.8M in cash. We note that this does not include revenues from the Astero Acquisition (completed in April)." (5/22/2019)
- 3. Northland Securities analysts commented, "We continue to believe BioLife is one of the better small-cap plays with a lower risk exposure to the biotech / regen med space. Maintain OP rating." (5/13/2019)
Has BioLife Solutions been receiving favorable news coverage?
Media stories about BLFS stock have been trending positive this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioLife Solutions earned a news impact score of 2.5 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for BioLife Solutions.
Are investors shorting BioLife Solutions?
BioLife Solutions saw a decline in short interest in July. As of July 31st, there was short interest totalling 1,266,800 shares, a decline of 5.7% from the June 30th total of 1,343,500 shares. Based on an average daily volume of 194,100 shares, the days-to-cover ratio is currently 6.5 days. Currently, 9.8% of the company's shares are short sold. View BioLife Solutions' Current Options Chain.
Who are some of BioLife Solutions' key competitors?
Some companies that are related to BioLife Solutions include Natus Medical (NTUS), Natus Medical (BABY), IntegraMed America, Incorporation. (INMD), AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), Viewray (VRAY), Zynex (ZYXI), Semler Scientific (SMLR), Stereotaxis (STXS), Rockwell Medical (RMTI), BioSig Technologies (BSGM), Fonar (FONR), Fc Global Realty (FCRE) and Edap Tms (EDAP).
What other stocks do shareholders of BioLife Solutions own?
Who are BioLife Solutions' key executives?
BioLife Solutions' management team includes the folowing people:
- Mr. Michael P. Rice, Pres, CEO & Director (Age 56)
- Mr. Roderick de Greef, CFO & Sec. (Age 59)
- Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 47)
- Ms. Karen Foster, VP of Operations (Age 59)
- Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance
Who are BioLife Solutions' major shareholders?
BioLife Solutions' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sandler Capital Management (4.62%), Vanguard Group Inc. (3.34%), BlackRock Inc. (2.88%), Russell Investments Group Ltd. (1.59%), Essex Investment Management Co. LLC (1.18%) and Allianz Asset Management GmbH (1.15%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Greef Roderick De, James Mathers, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View Institutional Ownership Trends for BioLife Solutions.
Which major investors are selling BioLife Solutions stock?
BLFS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sandler Capital Management, Essex Investment Management Co. LLC, Granite Investment Partners LLC, Bank of Montreal Can, Wells Fargo & Company MN, Cadence Capital Management LLC and Magnus Financial Group LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Andrew G Hinson, Greef Roderick De, James Mathers, Joseph C Schick, Michael Rice, Raymond W Cohen, Todd Berard and Walter Villiger. View Insider Buying and Selling for BioLife Solutions.
Which major investors are buying BioLife Solutions stock?
BLFS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Roubaix Capital LLC, Citadel Advisors LLC, Penbrook Management LLC, Charles Schwab Investment Management Inc., Allianz Asset Management GmbH and Ancora Advisors LLC. View Insider Buying and Selling for BioLife Solutions.
How do I buy shares of BioLife Solutions?
Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioLife Solutions' stock price today?
One share of BLFS stock can currently be purchased for approximately $20.28.
How big of a company is BioLife Solutions?
BioLife Solutions has a market capitalization of $385.32 million and generates $19.74 million in revenue each year. The medical equipment provider earns $3.27 million in net income (profit) each year or $0.14 on an earnings per share basis. BioLife Solutions employs 54 workers across the globe.View Additional Information About BioLife Solutions.
What is BioLife Solutions' official website?
How can I contact BioLife Solutions?
BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]
MarketBeat Community Rating for BioLife Solutions (NASDAQ BLFS)
MarketBeat's community ratings are surveys of what our community members think about BioLife Solutions and other stocks. Vote "Outperform" if you believe BLFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
